Healio Rheumatology, November 2017
Gary S. Hoffman, MD, MS, MACR
I am thrilled to have Gary S. Hoffman, MD, MS, MACR, write this month’s Guest Editorial for Healio Rheumatology. No one, in my judgment, is better qualified to help us consider how the recent advances in giant cell arteritis will ultimately effect the way we treat the disease and, of course, ultimately how our patients can potentially benefit from these changes. New therapies must be critically appraised based on a skillful weighing of benefits and risk. We are fortunate to have one of the sages of vasculitis guide us through this process.
— Leonard H. Calabrese, DO